Free Trial
NASDAQ:NPCE

NeuroPace (NPCE) Stock Price, News & Analysis

NeuroPace logo
$9.11 +0.23 (+2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$8.96 -0.15 (-1.64%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeuroPace Stock (NASDAQ:NPCE)

Key Stats

Today's Range
$8.85
$9.16
50-Day Range
$8.25
$11.14
52-Week Range
$5.45
$18.98
Volume
151,897 shs
Average Volume
208,653 shs
Market Capitalization
$301.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Moderate Buy

Company Overview

NeuroPace Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

NPCE MarketRank™: 

NeuroPace scored higher than 61% of companies evaluated by MarketBeat, and ranked 430th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    NeuroPace has only been the subject of 2 research reports in the past 90 days.

  • Read more about NeuroPace's stock forecast and price target.
  • Earnings Growth

    Earnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroPace is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroPace is -10.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeuroPace has a P/B Ratio of 15.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about NeuroPace's valuation and earnings.
  • Percentage of Shares Shorted

    4.89% of the float of NeuroPace has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroPace has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroPace has recently increased by 23.81%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NeuroPace does not currently pay a dividend.

  • Dividend Growth

    NeuroPace does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.89% of the float of NeuroPace has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroPace has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroPace has recently increased by 23.81%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NeuroPace has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for NeuroPace this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for NPCE on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroPace insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NeuroPace's insider trading history.
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NPCE Stock News Headlines

NeuroPace to Participate in Upcoming Healthcare Conferences
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
See More Headlines

NPCE Stock Analysis - Frequently Asked Questions

NeuroPace's stock was trading at $11.19 at the beginning of 2025. Since then, NPCE shares have decreased by 18.6% and is now trading at $9.11.

NeuroPace, Inc. (NASDAQ:NPCE) posted its earnings results on Tuesday, August, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.02. The company had revenue of $23.52 million for the quarter, compared to the consensus estimate of $23.08 million. NeuroPace had a negative net margin of 29.29% and a negative trailing twelve-month return on equity of 168.61%.
Read the conference call transcript
.

NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

NeuroPace's top institutional investors include Orbimed Advisors LLC (7.97%), Soleus Capital Management L.P. (6.99%), First Light Asset Management LLC (4.21%) and Armistice Capital LLC (3.51%). Insiders that own company stock include Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Ltd Kck.
View institutional ownership trends
.

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NPCE
CIK
1528287
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$15.00
Potential Upside/Downside
+82.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.14 million
Net Margins
-29.29%
Pretax Margin
-29.29%
Return on Equity
-168.61%
Return on Assets
-25.48%

Debt

Debt-to-Equity Ratio
3.02
Current Ratio
5.47
Quick Ratio
4.51

Sales & Book Value

Annual Sales
$79.91 million
Price / Sales
3.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.59 per share
Price / Book
15.44

Miscellaneous

Outstanding Shares
33,080,000
Free Float
26,299,000
Market Cap
$301.36 million
Optionable
Optionable
Beta
1.89
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:NPCE) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners